Compare Natera Inc. Common Stock (NTRA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Under Armour Inc Class A trades at $4.83 (market cap $2.03B). The key difference: Natera Inc. Common Stock is far larger — about 28.1× Under Armour Inc Class A's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| NTRA | UAA | |
|---|---|---|
Market Cap | $57.03B | $2.03B |
Volume | 1,131,157 | 7,140,862 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $8.14 |
52-Week Low | $179.42 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $56.18B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Under Armour (UAA) trades at $4.90, down 0.61% on the day, with a mixed technical signal showing a bullish moving average trend but overbought RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a 'Hold' with a $5.79 price target, while cash flow trends remain negative, highlighting financial strain amid a brand transformation.
The outlook is cautious; margin improvements and international growth offer potential, but persistent revenue weakness and negative cash flows pose significant risks. Investors face a balance between turnaround execution under new strategies and ongoing demand challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
